Novartis AG ((NVS)), DEL_Novartis (0QM7) ((DEL_0QM7)), DEL_Novartis Inc ((DEL_0QLR)), Novartis ((CH:NOVN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Novartis AG is collaborating with Olema Pharmaceuticals on a Phase 1b clinical study titled A Phase 1b Open-Label Multicenter Study of OP-1250 (Palazestrant) in Combination With the CDK4/6 Inhibitor Ribociclib, With the PI3K Inhibitor Alpelisib, or With the mTOR Inhibitor Everolimus in Adult Subjects With Advanced and/or Metastatic ER Positive, HER2 Negative Breast Cancer. The study aims to evaluate the safety and pharmacokinetics of Palazestrant in combination with three different inhibitors, targeting advanced breast cancer treatment.
The study tests Palazestrant, a complete estrogen receptor antagonist, in combination with Ribociclib, Alpelisib, and Everolimus. These combinations aim to enhance treatment efficacy in ER+, HER2- breast cancer.
This interventional study is non-randomized with a parallel intervention model and no masking, focusing on treatment as the primary purpose. It includes two parts: dose escalation and dose expansion, to determine the optimal dosing and explore anti-tumor activity.
The study began on August 31, 2022, with an estimated completion update submitted on August 12, 2025. These dates are crucial for tracking progress and anticipating results that could influence market dynamics.
As the study progresses, it could impact Novartis’s stock performance positively if successful, given the potential for new treatment options in a competitive oncology market. Investors should monitor updates closely, considering the broader industry context.
The study is ongoing, and further details are available on the ClinicalTrials portal.